CARMIEL, Israel, May 22, 2020 Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production, and marketing of recombinant therapeutic proteins manufactured by ProCellEx® The plant cell-based protein expression system announced today that it will release its first quarter 2020 financial results and business update on Monday, June 1, 2020. Management of the company will hold a conference call to discuss financial results and make a general statement about the business update at 8:30 am Eastern Daylight Time (EDT).
Conference Call Details:
Monday, June 1, 2020, 8:30 a.m.Eastern Daylight Time (EDT)
Conference ID: 13704328
Webcast link: https://tinyurl.com/yc32s9jn
Conference ID: 13704328
The conference call will also be broadcast live and can be repeated on the company's website for two weeks. www.protalix.com, in the events calendar of the Investors section. Please access the company's website at least 15 minutes prior to the conference to register, download and install the required audio software.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins that are expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to receive approval for a protein by the United States Food and Drug Administration (FDA) for a suspension expression system based on plant cells. Protalix's unique expression system represents a new method for developing recombinant proteins on an industrial scale.
The first Protalix product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and subsequently by regulatory agencies in other countries. Protalix has licensed Pfizer Inc. worldwide development and commercialization rights for Taliglucerase alfa with the exception of Brazil, where Protalix retains full rights.
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets, including the following product candidates: Pegunigalsidase alfa, a modified version of the recombinant human α-galactosidase A protein for the proposed treatment of Fabry disease; OPRX-106, an oral anti-inflammatory treatment; Alidornase alfa for the treatment of cystic fibrosis; and other. Protalix has partnered with Chiesi Farmaceutici S.p.A. partnered both in the US and outside the US to develop and market pegunigalsidase alfa.
Chuck Padala, managing director
View original content to download multimedia:http://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-hold-first-quarter-2020-financial-results-and-business-update-conference-call-on-june-1-2020- 301064204.html
SOURCE Protalix BioTherapeutics, Inc.